Oxaliplatin

Generic Name: Oxaliplatin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₄N_₂O_₄Pt

CAS Number: 61825-94-3

Unique Ingredient Identifier: 04ZR38536J

Background: Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The DACH moiety also prevents cross-resistance with cisplatin and carboplatin.

Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer. This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer.

Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®.

Indication: Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.

Associated Conditions: Advanced Colorectal Cancer, Stage III Colon Cancer

Associated Therapies: -

Clinical Trials

Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases

Phase 2

Conditions: Colorectal Cancer

Interventions: Drug: Cetuximab
Drug: Bevacizumab
Drug: Irinotecan
Drug: 5-FU
Drug: Oxaliplatin
Drug: Folinic Acid

First Posted Date: 2013-03-01

Last Posted Date: 2019-09-11

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 91

Registration Number: NCT01802645

Locations: 🇩🇪
Klinikum Coburg GmbH, Coburg, Germany
🇩🇪
Klinikum Landshut gGmbH, Landshut, Germany
🇩🇪
Rems-Murr-Klinikum Winnenden, Winnenden, Germany

and more 12 locations

XELOX With Capecitabine Maintenance or XELOX in Elderly Metastatic Adenocarcinoma of Stomach

Phase 2

Conditions: Gastric Cancer

Interventions: Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2013-02-25

Last Posted Date: 2013-05-06

Lead Sponsor: Harbin Medical University

Target Recruit Count: 40

Registration Number: NCT01798251

Locations: 🇨🇳
The tumor hospital of Harbin medical university, Harbin, Heilongjiang, China

Sorafenib + mFOLFOX for Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Cancer

Interventions: Drug: Leucovorin
Drug: Fluorouracil
Drug: Oxaliplatin
Drug: Sorafenib

First Posted Date: 2013-01-25

Last Posted Date: 2020-04-22

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 40

Registration Number: NCT01775501

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

Phase 2

Terminated

Conditions: HER2 Positive Esophagogastric Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Oxaliplatin
Drug: Lapatinib
Radiation: Radiation Therapy

First Posted Date: 2013-01-16

Last Posted Date: 2016-06-13

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 12

Registration Number: NCT01769508

Locations: 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists-North, St. Petersburg, Florida, United States
🇺🇸
Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States

and more 6 locations

Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Neoplasms

Interventions: Drug: 5-fluorouracil
Drug: bevacizumab
Drug: capecitabine
Drug: irinotecan
Drug: folinic acid
Drug: oxaliplatin

First Posted Date: 2013-01-10

Last Posted Date: 2017-09-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 280

Registration Number: NCT01765582

Locations: 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸
Johns Hopkins Univ; Bunting Blaustein Cancer Center, Baltimore, Maryland, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

and more 42 locations

A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer

Interventions: Drug: Oxaliplatin
Radiation: Radiation
Drug: Capecitabine
Drug: Trastuzumab

First Posted Date: 2012-12-13

Last Posted Date: 2019-10-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 34

Registration Number: NCT01748773

Locations: 🇹🇷
Marmara Uni Faculty of Medicine; Medical Oncology, Istanbul, Turkey
🇹🇷
Baskent University Medical Faculty; Internal Medicine, Ankara, Turkey
🇹🇷
Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey

and more 6 locations

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil
Drug: Ziv-aflibercept

First Posted Date: 2012-12-11

Last Posted Date: 2020-02-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 64

Registration Number: NCT01747551

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer

Phase 2

Conditions: Inoperable Esophageal Cancer Stage I-III

Interventions: Radiation: Radiotherapy
Drug: Raltitrexed
Drug: Oxaliplatin

First Posted Date: 2012-11-22

Last Posted Date: 2012-11-22

Lead Sponsor: The First People's Hospital of Lianyungang

Target Recruit Count: 108

Registration Number: NCT01732380

Locations: 🇨🇳
The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China

Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer

Phase 2

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Erlotinib
Drug: Folinic Acid
Drug: Irinotecan
Drug: 5-FU

First Posted Date: 2012-11-20

Last Posted Date: 2017-07-19

Lead Sponsor: Ludwig-Maximilians - University of Munich

Target Recruit Count: 150

Registration Number: NCT01729481

Locations: 🇩🇪
University of Munich, Munich, Germany

NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)

Phase 3

Completed

Conditions: Adenocarcinoma of the Oesophagus
Oesophageal Tumours
Junctional Tumours
Adenocarcinoma of the Oesophago-gastric Junction
Oesophageal Cancer

Interventions: Radiation: (41.4 Gy/23 fractions)
Drug: Epirubicin
Drug: Cisplatin / Oxaliplatin
Drug: Paclitaxel
Drug: 5 Flourouracil/ Capecitabine
Drug: Carboplatin
Drug: Docetaxel
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-Fluorouracil

First Posted Date: 2012-11-15

Last Posted Date: 2022-09-30

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 377

Registration Number: NCT01726452

Locations: 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Box 279(s4), Cambridge Biomedical Camp, Cambridge, United Kingdom
🇸🇪
Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
🇬🇧
Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham, United Kingdom

and more 26 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy